Reported / Citable
Background
In September 2022, fentanyl killed a young person in Goleta, California. Federal agents traced the drugs back to Isaac Tekola, who had been dealing from his apartment in the Central District of California for years. A search of his apartment turned up nearly $13,000 in cash, drug paraphernalia including a pay-owe sheet, baggies, a vacuum sealer, and scales with residue, plus large quantities of cocaine, fentanyl pills, and counterfeit Adderall laced with methamphetamine. Tekola admitted the cash came from drug dealing and that a bedroom safe was primarily used to store drugs and proceeds.
Tekola pleaded guilty to possession with intent to distribute fentanyl, cocaine, methamphetamine, and Alprazolam. At sentencing, the district court imposed a two-level enhancement under U.S. Sentencing Guideline § 2D1.1(b)(12) for maintaining a premises for drug manufacturing or distribution, and sentenced Tekola to 105 months. Tekola appealed, arguing the enhancement should not apply because the apartment was his primary residence, not a “stash house.”
The Court’s Holding
The Ninth Circuit affirmed. The court held that the § 2D1.1(b)(12) enhancement does not require drug trafficking to be the sole purpose of the premises—it need only be “one of the defendant’s primary or principal uses.” Following sister circuits, the panel found that overwhelming evidence showed Tekola’s apartment was the central hub of his distribution network: he stored drugs there, processed and packaged them in his bedroom, maintained tools of the trade throughout the apartment, and regularly conducted sales from the location.
The court distinguished its earlier decision in United States v. Shetler, which had interpreted the related criminal statute 21 U.S.C. § 856(a)(1) more narrowly to avoid constitutional vagueness concerns. The panel explained that those concerns do not apply to sentencing guidelines, which merely guide judicial discretion and are not subject to vagueness challenges under Beckles v. United States (2017). The enhancement is also narrower than the statute because it requires “maintaining” premises for “manufacturing or distributing”—not merely “using” any controlled substance.
Key Takeaways
- The § 2D1.1(b)(12) sentencing enhancement for maintaining a drug premises applies even when the location is the defendant’s primary residence, as long as drug trafficking is a “primary or principal use.”
- A district court need not explicitly compare the frequency of “residential use” versus “drug use” of the premises—the totality of the evidence governs.
- The Ninth Circuit’s prior narrow construction of 21 U.S.C. § 856(a)(1) in Shetler does not control interpretation of the sentencing guideline enhancement, because guidelines are not subject to vagueness challenges.
- Key factors supporting the enhancement include: large drug quantities stored on-site, drug-dealing paraphernalia, cash from sales, regular customer transactions at the location, and defendant admissions about the premises’ drug-related use.
Why It Matters
This decision closes the door on the argument that living in a residence immunizes a drug dealer from the § 2D1.1(b)(12) enhancement. For federal criminal defense attorneys in the Central District and across the Ninth Circuit, the practical takeaway is clear: if a defendant operates a significant drug business from home—storing product, packaging it, and conducting sales there—the enhancement will apply regardless of whether the apartment also serves ordinary residential purposes. The court’s distinction between the criminal statute in Shetler and the sentencing guideline is also significant, as it frees district courts from the narrower “primary or principal use” analysis previously required for the underlying criminal offense.